Refine by
Neurologist Articles & Analysis: Older
440 news found
In the ever-evolving landscape of pharmaceutical research and development, the demand for innovative and efficient drug discovery methods is more pressing than ever. At the forefront of this demanding field is Protheragen-ING AI-Pharma, a contract research and development biotechnology company, offering cutting-edge solutions to researchers through its AI-powered drug discovery and design ...
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. Following with the announcement of developing small molecule drug for glaucoma, Ace Therapeutics recently unveiled disease model customization services to accelerate ...
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. With the rise of antibiotic-resistant bacteria posing a significant threat to global public health, Ace Therapeutics announces its new vaccine development services to ...
CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare ...
Anuncia Medical Inc. (“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems, is pleased to announce the successful first implant of the Company’s FDA-cleared ReFlow™ Mini Flusher device in tandem with a “sonolucent” cranial plate (Clearfit® Cover, ...
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, proudly announces an extensive portfolio of Nervous System Tissue Microarrays designed to support neuroscience research. This comprehensive collection provides researchers with a unique resource to study various neurological conditions and accelerate their investigations into neurological ...
Surgeons at Intermountain Primary Children’s Hospital are the first in the nation to successfully implant a new brain shunt accessory for young patients with hydrocephalus, a neurological condition that causes a buildup of cerebrospinal fluid in the deep cavities of the brain that often causes frequent hospitalizations. This extra fluid puts pressure on the brain and can cause brain ...
NHL Alumni Association (NHLAA), NEEKA Health Canada("NEEKA"),and CanaQuest Medical Corp ("CanaQuest") are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® as a potential treatment to reduce anxiety in former NHL ...
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced a new partnership with Perigon Pharmacy 360, a full-service, specialty digital pharmacy, to enhance accessibility, affordability and adherence for patients treating symptoms of ADHD with Tris’ ...
In the pursuit of advancing disease research and its treatment, animal cognitive behavior is studied in a wide range of animal species. The innovative multi-type animal cognitive behavioral tests are set to complement disease research methodology, enabling scientists to gain deeper insight into the complexities of cognitive functioning and its implications in various pathological conditions. ...
In today’s fast-paced and stressful society, the prevalence of anxiety and depression has become a significant concern. Emotion-related animal behavior tests aim to provide a good research tool for the study of emotion-associated diseases. Anxiety and depression affect millions of individuals worldwide, leading to a significant burden on public health and impacting overall quality of ...
Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain, addiction and neurological disorders, today announced that Health Canada has authorized the use of Quillivant® ER (extended release) for the treatment of attention deficit hyperactivity disorder (ADHD) in children ages 6 to 12. Quillivant ER will be available as both an oral ...
We believe we can provide a safer alternative to other THC products providing the benefits without the negative psychiatric side effects. Pre-clinical trials have demonstrated the reversal of depression-like and schizophrenia-related symptoms, blockage of memory impairment, hyperactive activity, and gene vulnerability. CanaQuest Medical Corp ("CanaQuest" or the "Company") (OTC:CANQF), a ...
Semper Paratus Acquisition Corporation (Nasdaq: LGST) (“Semper Paratus”), a publicly traded special purpose acquisition company, today announced the filing of a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission relating to Semper Paratus’ previously announced proposed business combination with Tevogen ...
Positive results confirm findings from prior studies evaluating the abuse potential of cebranopadol, further highlighting its potential as a safe and potent alternative to traditional opioids Registrational phase 3 clinical trials of cebranopadol in moderate to severe acute pain are on track to initiate in Q4 2023 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage ...
Intermountain Primary Children’s Hospital First in the Country to Implant this Next Generation FDA-Cleared Device Company Welcomes Vice President of Sales & Marketing, Mark Geiger, Who Lives with Hydrocephalus Anuncia Medical Inc. (“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid ...
After struggling to conceive a child for what felt like ages, Miranda of Moncks County, South Carolina finally fell pregnant - a miracle that quickly turned into horror when she delivered at 24 weeks in late 2015. At just 1 pound and 12 ounces, her son, Sutton, arrived with life-threatening health issues, including hydrocephalus - a neurological disorder caused by an abnormal buildup of ...
Canaquest Medical Corp (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth annual Healthcare and Pharmaceutical ...
With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has recently launched its new line of PLGA-based drug delivery systems for in vitro and in vivo applications, including biocompatible and biodegradable PLGA nanoparticles with different surface modifications (e.g., COOH groups, methoxy PEG, and PEG-azide). In recent years, the development of nanotechnology ...
Thomas Englese, a 20+ year industry veteran with a track record of success at leading biopharmaceutical companies, joins as chief commercial officer Marc Lesnick, Ph.D., appointed as chief development officer, bringing more than 20 years of experience in multiple therapeutic areas Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological ...